30/04/2019 – AB Science reports its annual financial results as of 31 December 2018. Post navigationPreviousPrevious post:Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association ConferenceNextNext post:Lifting of the ANSM clinical holdRelated PostsPublication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS23 December 2019Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood9 December 2019Webcast on masitinib in severe asthma on Monday, December 2, 201926 November 2019Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis25 November 2019Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities22 November 2019Positive top-line Phase 3 results for masitinib in severe asthma7 November 2019
Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS23 December 2019
Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood9 December 2019
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities22 November 2019